Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

Tarih
2021
Yazar
Spigel, David
Uslu, Ruchan
Krzakowski, Maciej
Lee, Jong-Seok
Calabro, Luana
Frontera, Osvaldo Aren
Xiong, Huiling
Bajars, Marcis
Ruisi, Mary
Barlesi, Fabrice
Park, Keunchil
ÖZGÜROĞLU, Mustafa
Vansteenkiste, Johan
Yang, James C. H.
Ishii, Hidenobu
Garassino, Marina
de Marinis, Filippo
Szczesna, Aleksandra
Polychronis, Andreas
Üst veri
Tüm öğe kaydını göster
Özet
Introduction: In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.
Bağlantı
http://hdl.handle.net/20.500.12627/175331
https://doi.org/10.1016/j.jtho.2021.03.009
Koleksiyonlar